Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit

Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit




Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit

Poster presentation to address the preclinical cannabidiol derivative for the potential treatment of psychiatric disorders

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that researchers from the Johns Hopkins University School of Medicine will present the results of new research on the company’s compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit. The poster presentation will discuss the preclinical cannabidiol (CBD) derivative that targets endogenous cannabinoid receptor type 2 for the treatment of psychiatric disorders. The researchers studied the compound in depression and anxiety-related phenotypes in mice.

“This presentation of preclinical research will highlight the potential of Supera-CBD to address unmet needs in psychiatry,” said Adam Kaplin, M.D., Ph.D., Chief Scientific Officer of MyMD Pharmaceuticals.

Researchers Chantelle Terrillion, Ph.D., Instructor in Neuroscience, and Anupama Kumar, MBBS, Research Associate in Psychiatry and primary investigator on the study, will present findings from preclinical studies on the role of Supera-CBD. Early findings revealed Supera-CBD’s potent anxiolytic properties. The data being presented at the conference also demonstrate that Supera-CBD binds to CB2 with almost four-times the affinity of CBD. Other research has shown that binding to CB2 potentially mediates a number of the therapeutic effects of CBD, including its anxiolytic, antinociceptive, anticonvulsant, antipsychotic, neuroprotective and anti-inflammatory effects.

Details of the poster presentation are as follows:

Title: Supera-CBD: A Novel CBD Derived Drug Candidate

Abstract Number: 1858

Date and Time: April 28, 2021 at 4:15 p.m. ET.

Access to Poster: The poster will be available at the conference website’s media library as well as on MyMD.com/pipeline/supera-cbd after the time noted above.

About MyMD Pharmaceuticals, Inc.

MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, and aging and longevity. Supera-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would” and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates, the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates, the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the registration statement on Form S-4 filed by MyMD on January 15, 2021, as amended. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Contact:
Brett Mass

646-536-7331

brett@haydenir.com
www.haydenir.com

Media Contact:
Will Johnson

201-465-8019

MYMD@antennagroup.com
www.antennagroup.com